Gold Silver Reports (GSR) – Shares of the drugmaker rose as much as 4.2 percent to trade over a 14-month high at Rs 614.25.
The pharmaceutical company received a green signal from the U.S. drug regulator for its Bimatoprost Ophthalmic solution, according to its statement on the exchanges. The frug is used to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness, the statement added.
The Relative Strength Index was 75, indicating that the stock may be overbought. – Neal Bhai Reports (NBR)
